Physician Attitudes towards Pharmacological Cognitive Enhancement: Safety Concerns Are Paramount
Open Access
- 14 December 2010
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 5 (12) , e14322
Abstract
The ethical dimensions of pharmacological cognitive enhancement have been widely discussed in academic circles and the popular media, but missing from the conversation have been the perspectives of physicians - key decision makers in the adoption of new technologies into medical practice. We queried primary care physicians in major urban centers in Canada and the United States with the aim of understanding their attitudes towards cognitive enhancement. Our primary hypothesis was that physicians would be more comfortable prescribing cognitive enhancers to older patients than to young adults. Physicians were presented with a hypothetical pharmaceutical cognitive enhancer that had been approved by the regulatory authorities for use in healthy adults, and was characterized as being safe, effective, and without significant adverse side effects. Respondents overwhelmingly reported increasing comfort with prescribing cognitive enhancers as the patient age increased from 25 to 65. When asked about their comfort with prescribing extant drugs that might be considered enhancements (sildenafil, modafinil, and methylphenidate) or our hypothetical cognitive enhancer to a normal, healthy 40 year old, physicians were more comfortable prescribing sildenafil than any of the other three agents. When queried as to the reasons they answered as they did, the most prominent concerns physicians expressed were issues of safety that were not offset by the benefit afforded the individual, even in the face of explicit safety claims. Moreover, many physicians indicated that they viewed safety claims with considerable skepticism. It has become routine for safety to be raised and summarily dismissed as an issue in the debate over pharmacological cognitive enhancement; the observation that physicians were so skeptical in the face of explicit safety claims suggests that such a conclusion may be premature. Thus, physician attitudes suggest that greater weight be placed upon the balance between safety and benefit in consideration of pharmacological cognitive enhancement.Keywords
This publication has 36 references indexed in Scilit:
- Distinguishing Between Restoration and Enhancement in NeuropharmacologyAMA Journal of Ethics, 2010
- Enhancement's place in medicineJournal of Medical Ethics, 2010
- Responding to requests from adult patients for neuroenhancementsNeurology, 2009
- The Perils of Cognitive Enhancement and the Urgent Imperative to Enhance the Moral Character of HumanityJournal of Applied Philosophy, 2008
- Ethical Transparency and Economic MedicalizationJournal of Business Ethics, 2008
- Improving our Brains?BioSocieties, 2006
- Neuroethics of Cognitive EnhancementBioSocieties, 2006
- Is It Ethical to Use Enhancement Technologies to Make Us Better than Well?PLOS Medicine, 2004
- 'Smart Drugs': do they work? Are they ethical? Will they be legal?Nature Reviews Neuroscience, 2002
- Age‐associated memory impairment: Proposed diagnostic criteria and measures of clinical change — report of a national institute of mental health work groupDevelopmental Neuropsychology, 1986